Axsome Therapeutics (AXSM) Competitors $127.15 -0.39 (-0.31%) Closing price 04:00 PM EasternExtended Trading$126.66 -0.50 (-0.39%) As of 05:32 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends AXSM vs. ONC, TEVA, GMAB, SMMT, ITCI, VTRS, MRNA, RDY, PCVX, and SRPTShould you be buying Axsome Therapeutics stock or one of its competitors? The main competitors of Axsome Therapeutics include Beigene (ONC), Teva Pharmaceutical Industries (TEVA), Genmab A/S (GMAB), Summit Therapeutics (SMMT), Intra-Cellular Therapies (ITCI), Viatris (VTRS), Moderna (MRNA), Dr. Reddy's Laboratories (RDY), Vaxcyte (PCVX), and Sarepta Therapeutics (SRPT). These companies are all part of the "pharmaceutical products" industry. Axsome Therapeutics vs. Beigene Teva Pharmaceutical Industries Genmab A/S Summit Therapeutics Intra-Cellular Therapies Viatris Moderna Dr. Reddy's Laboratories Vaxcyte Sarepta Therapeutics Axsome Therapeutics (NASDAQ:AXSM) and Beigene (NASDAQ:ONC) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their risk, valuation, analyst recommendations, profitability, media sentiment, earnings, community ranking, dividends and institutional ownership. Which has better earnings & valuation, AXSM or ONC? Axsome Therapeutics has higher earnings, but lower revenue than Beigene. Beigene is trading at a lower price-to-earnings ratio than Axsome Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAxsome Therapeutics$385.69M16.08-$287.22M-$5.99-21.23Beigene$3.81B6.31-$881.71M-$6.14-39.99 Which has more volatility and risk, AXSM or ONC? Axsome Therapeutics has a beta of 1.05, meaning that its stock price is 5% more volatile than the S&P 500. Comparatively, Beigene has a beta of 0.63, meaning that its stock price is 37% less volatile than the S&P 500. Do analysts prefer AXSM or ONC? Axsome Therapeutics presently has a consensus price target of $167.36, indicating a potential upside of 31.62%. Beigene has a consensus price target of $316.50, indicating a potential upside of 28.90%. Given Axsome Therapeutics' higher probable upside, equities analysts plainly believe Axsome Therapeutics is more favorable than Beigene.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Axsome Therapeutics 0 Sell rating(s) 0 Hold rating(s) 15 Buy rating(s) 0 Strong Buy rating(s) 3.00Beigene 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the MarketBeat Community believe in AXSM or ONC? Axsome Therapeutics received 472 more outperform votes than Beigene when rated by MarketBeat users. However, 100.00% of users gave Beigene an outperform vote while only 70.33% of users gave Axsome Therapeutics an outperform vote. CompanyUnderperformOutperformAxsome TherapeuticsOutperform Votes47470.33% Underperform Votes20029.67% BeigeneOutperform Votes2100.00% Underperform VotesNo Votes Do institutionals and insiders hold more shares of AXSM or ONC? 81.5% of Axsome Therapeutics shares are held by institutional investors. Comparatively, 48.5% of Beigene shares are held by institutional investors. 22.4% of Axsome Therapeutics shares are held by company insiders. Comparatively, 7.4% of Beigene shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Does the media favor AXSM or ONC? In the previous week, Beigene had 7 more articles in the media than Axsome Therapeutics. MarketBeat recorded 32 mentions for Beigene and 25 mentions for Axsome Therapeutics. Axsome Therapeutics' average media sentiment score of 0.27 beat Beigene's score of 0.09 indicating that Axsome Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Axsome Therapeutics 4 Very Positive mention(s) 3 Positive mention(s) 8 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Beigene 6 Very Positive mention(s) 4 Positive mention(s) 12 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Is AXSM or ONC more profitable? Beigene has a net margin of -25.94% compared to Axsome Therapeutics' net margin of -74.47%. Beigene's return on equity of -25.12% beat Axsome Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Axsome Therapeutics-74.47% -223.51% -39.88% Beigene -25.94%-25.12%-14.95% SummaryAxsome Therapeutics beats Beigene on 11 of the 17 factors compared between the two stocks. Get Axsome Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for AXSM and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AXSM vs. The Competition Export to ExcelMetricAxsome TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$6.20B$7.21B$5.81B$8.39BDividend YieldN/A2.79%4.75%3.98%P/E Ratio-21.236.1524.9519.21Price / Sales16.08187.68375.54110.22Price / CashN/A65.6738.0534.58Price / Book107.756.447.334.28Net Income-$287.22M$139.03M$3.18B$247.04M7 Day Performance-2.73%-5.52%-4.42%-4.36%1 Month Performance18.36%-8.56%-6.07%-5.60%1 Year Performance54.27%-14.59%11.42%3.38% Axsome Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AXSMAxsome Therapeutics4.7444 of 5 stars$127.15-0.3%$167.36+31.6%+54.7%$6.20B$385.69M-21.23380Analyst ForecastONCBeigene2.4575 of 5 stars$258.36+1.2%N/AN/A$25.28B$2.46B-31.3510,600Earnings ReportAnalyst ForecastInsider TradeAnalyst RevisionNews CoverageGap DownTEVATeva Pharmaceutical Industries3.1216 of 5 stars$16.83+0.5%$23.57+40.1%+21.9%$19.08B$16.54B-11.6136,830Short Interest ↑GMABGenmab A/S4.3716 of 5 stars$22.52+0.8%$42.17+87.2%-22.6%$14.89B$3.12B12.932,204Positive NewsSMMTSummit Therapeutics2.5734 of 5 stars$18.85-14.8%$33.57+78.1%+344.9%$13.92B$700,000.00-67.40110Earnings ReportAnalyst ForecastAnalyst RevisionHigh Trading VolumeITCIIntra-Cellular Therapies3.9106 of 5 stars$128.590.0%$106.08-17.5%+79.3%$13.67B$612.78M-147.83560Options VolumeGap UpVTRSViatris3.5027 of 5 stars$11.42+1.5%$13.67+19.7%-26.7%$13.61B$15.43B-15.4138,000Earnings ReportDividend AnnouncementAnalyst ForecastMRNAModerna4.5064 of 5 stars$34.03-4.2%$60.63+78.2%-67.4%$13.16B$3.24B-3.685,600RDYDr. Reddy's Laboratories2.6236 of 5 stars$13.48+1.0%$17.00+26.1%-14.7%$11.25B$3.35B21.4627,048PCVXVaxcyte2.223 of 5 stars$82.24+3.1%$127.71+55.3%+1.8%$10.22BN/A-17.82160Earnings ReportAnalyst RevisionSRPTSarepta Therapeutics4.5739 of 5 stars$106.54+0.2%$176.77+65.9%-17.0%$10.16B$1.64B85.081,314 Related Companies and Tools Related Companies ONC Alternatives TEVA Alternatives GMAB Alternatives SMMT Alternatives ITCI Alternatives VTRS Alternatives MRNA Alternatives RDY Alternatives PCVX Alternatives SRPT Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:AXSM) was last updated on 3/3/2025 by MarketBeat.com Staff From Our PartnersDOGE Social Security bombshell?Elon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | SponsoredElon Musk Wants to Audit Fort Knox—What It Means for Your RetirementYou can take advantage of the coming tariff-fueled gold melt-up right inside your IRA or 401(k) – 100% TAX-FRE...Colonial Metals | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredThis Crypto Is Set to Explode in FebruaryIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredThe Deep State Surveillance Plot To Sabotage President TrumpThere's a Trump approved IRS-loophole which allows you to steer clear of government overreach and move your re...American Hartford Gold | SponsoredTrump’s Victory Could Spark Major Gains for Gold – Don’t Miss Out This "Patriot's Tax Shield" lets you defend your wealth with real, solid gold. Our exclusive, free wealth pr...American Alternative | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Axsome Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Axsome Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free AXSM Stock Alerts